Entera's EB613, First-in-Class Oral PTH(1-34) Anabolic for Osteoporosis - Single Tablet Data Selected for Late Breaking Oral Presentation at ENDO 2026 Annual Meeting; Additional Oral Peptide Pipeline Data Accepted for Presentation
Stocks in this Quantisnow insightHealth Care
Historical context for ENTX
Across the 16 sessions after earlier ENTX headlines, the stock closed higher 7 times and lower 9 times, with a median move of 5.9% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | ENTX | SPY |
|---|---|---|---|
| May 11, 2026 | Entera Announces First Quarter 2026 Financial Results and Updates Across its Oral Peptide Programs | -10.0% | +0.2% |
| Apr 20, 2026 | BriefCast Publishes Transcript: Entera Bio's Osteoporosis KOL Roundtable on EB613 - Oral Anabolic Tablet Opportunity | +4.7% | -0.2% |
| Apr 14, 2026 | Entera Bio to Host Key Opinion Leader Webinar Highlighting the Osteoporosis Treatment Landscape and the Opportunity for EB613 | +0.9% | +1.2% |
| Apr 6, 2026 | Greenberg Traurig Represents Israel-based Entera Bio in $10M Private Placement Led by BVF Partners | -5.6% | +0.5% |
| Apr 2, 2026 | Entera Bio Announces Pricing of $10.0 Million Direct Investment by BVF Partners with Potential for up to $24.5 Million in Total Proceeds | +10.5% | +0.1% |
| Mar 30, 2026 | Entera Bio Announces Full Year 2025 Financial Results and Provides Business Updates | -11.5% | -0.3% |
Keep researching ENTX
Quantisnow market dataNASDAQ
ENTX
Entera Bio Ltd.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Listed since
- 2018
Get push alerts for ENTX
Full ENTX profile on Quantisnow Follow ENTX and get a push notification the moment its next story breaks.